Davern Capital Partners, Lp
- Regulatory AUM
- $715M
- Discretionary
- $715M
- Clients
- 3
- Avg AUM / client
- $238M
- Accounts
- 3
- Employees
- 4
AUM over time
Annual snapshots from Form ADV filings · as of Mar 27, 2026
Investments (13F portfolio — 17 positions, $364,540,245)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Pfizer Inc | COM | $44,757,891 | 1,593,942 | 12.3% | 6.26% |
| 2 | Regeneron Pharmaceuticals | COM | $34,614,272 | 44,800 | 9.5% | 4.84% |
| 3 | Insmed Inc | COM PAR $.01 | $29,852,538 | 182,562 | 8.19% | 4.17% |
| 4 | Ionis Pharmaceuticals Inc | COM | $29,052,546 | 386,903 | 7.97% | 4.06% |
| 5 | Natera Inc | COM | $28,791,760 | 143,966 | 7.9% | 4.03% |
| 6 | Biontech Se | SPONSORED ADS | $27,113,288 | 305,055 | 7.44% | 3.79% |
| 7 | Argenx Se | SPONSORED ADR | $25,591,611 | 35,045 | 7.02% | 3.58% |
| 8 | Eli Lilly & Co | COM | $25,090,406 | 27,279 | 6.88% | 3.51% |
| 9 | Royalty Pharma Plc | SHS CLASS A | $24,944,832 | 520,009 | 6.84% | 3.49% |
| 10 | Roivant Sciences Ltd | SHS | $24,193,125 | 873,398 | 6.64% | 3.38% |
| 11 | Legend Biotech Corp | SPONSORED ADS | $23,783,791 | 1,314,748 | 6.52% | 3.33% |
| 12 | Mineralys Therapeutics Inc | COM | $12,113,375 | 447,153 | 3.32% | 1.69% |
| 13 | Abivax Sa | SPONSORED ADS | $8,699,219 | 78,125 | 2.39% | 1.22% |
| 14 | Generate Biomedicines Inc | COM SHS | $7,397,500 | 591,800 | 2.03% | 1.03% |
| 15 | Procept Biorobotics Corp | COM | $6,532,612 | 261,200 | 1.79% | 0.91% |
| 16 | Structure Therapeutics Inc | SPONSORED ADS | $6,095,420 | 126,461 | 1.67% | 0.85% |
| 17 | Viridian Therapeutics Inc | COM | $5,916,059 | 302,457 | 1.62% | 0.83% |
Top 25 of 17 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 2 | $55.1M | 7.71% |
| Sovereign wealth funds and foreign official institutions | 1 | $660M | 92.3% |
Private funds (1)
Reported in Form ADV Section 7.B.(1), filing of Apr 2024 · $30.8M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Davern Capital Partners Master Fund, Lp master | Hedge Fund | Cayman Islands | $30.8M | 9 |
Private funds (1, $30.8M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Davern Capital Partners Master Fund, Lp | Hedge Fund | $30.8M | $5.0M | 9 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/27/2026 | 1.23 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
- • Portfolio management for businesses/institutional clients
Custody
Reported custodians
- Morgan Stanley $660M (92% of AUM) Mar 2026
Amounts as reported in ADV Item 5.K.(3) (custodians holding 10%+ of SMA assets).
Firm reports having custody of client funds or securities (Item 9.A).
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 27, 2026.
View current Form ADV (SEC/IAPD) ↗